Vertex's povetacicept shows positive phase 3 results in kidney disease, advancing toward FDA review

Vertex Pharmaceuticals announced successful phase 3 trial results for povetacicept, a drug targeting IgA nephropathy, a kidney disease. The data met analyst expectations and positions the company to seek accelerated FDA approval potentially by November.